System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Giancarlo Castaman is an expert in Hematology at Careggi University Hospital (Italy). As of October 2026, ScienceLeadR ranks Giancarlo Castaman in the top 1% of experts worldwide for Hemophilia A, Hemophilia B and Blood Platelet Disorders. Giancarlo Castaman has authored 569 publications, the most recent in 2026, and is an investigator in 33 clinical trials, 9 of them ongoing. SLR score: 2,187 (community average: 125). How the SLR is computed.

LeadR Profile

Giancarlo Castaman Careggi University Hospital Italy
2 187 ScienceLeadR Reputation 2187

Unlock

Register Login
Network Map

Hematology

Subspecialties: Genetics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1986 - 2026
Source: PubMed

Careggi University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 569

Citations

Citations: 18 225 1st author: 147 Last author: 51 Unique author: 15

Main journals

Blood 88
Haemophilia 66
J Thromb Haemost 57
Haematologica 44
Thromb Haemost 36

Best Journals

N Engl J Med 4
Lancet 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Burden of Treatment and Disease on People with Hemophilia: Global Real-World Survey.
PMID 42765079 — hemophilia a, cost of illness, therapeutics		Patient Prefer Adherence20260
Physical Activity, Bleeding Incidence and Health-Related Quality of Life, in Patients With Haemophilia A Without Inhibitors, Treated With Emicizumab: A Post-Hoc Descriptive Analysis of the Power Study Data.
PMID 42687476 — exercise, quality of life, hemorrhage, incidence, hemophilia a		Haemophilia20260
Call to action: identifying an underlying bleeding disorder in adolescents with heavy menstrual bleeding.
PMID 42598146 — menorrhagia, quality of life, hemorrhage, anemia, anemia, iron-deficiency, adolescent, diagnosis, iron deficiencies		Res Pract Thromb Haemost20260
Evolution of Hemophilia Management in Italy: Results from a Delphi Consensus Study.
PMID 42513655 — comorbidity, hemophilia a, therapeutics		J Clin Med20260
FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry.
PMID 42448013 — registries, hemorrhage, drug-related side effects and adverse reactions, hemophilia a, thrombosis, infant		J Thromb Haemost20260

Clinical Studies 33

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 15
N/A 8
Phase 1 3
Phase 2 2
Phase 2/Phase 3 2
Phase 4 2
Phase 1/Phase 2 1

By status:

Completed 16
Recruiting 9
Active not recruiting 4
Not yet recruiting 2
Terminated 1
Unknown 1

By type:

Interventional 25
Observational 8

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 2
multicentric5to9 2
multicentricup10 27

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A
2025-522435-33-00 — safety, hemophilia a, pharmacokinetics		Phase 3Recruiting2026
A Trial to Learn if REGV131 LNP1265 is Safe and Works to Help the Body Make Clotting Factor in Adult Patients with Hemophilia B
2023-507260-40-00 — factor ix, genes, hemophilia b, clustered regularly interspaced short palindromic repeats, safety, hemorrhage, hemophilia a, blood coagulation factors, therapeutics		Phase 1/Phase 2Recruiting2025
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A
2025-522434-32-00 — factor viii, safety, hemophilia a, pharmacokinetics		Phase 3Recruiting2026
A research study looking at how different doses of study medicine (Inno8) work in the body of people with haemophilia A
2025-520490-38-00 — work, hemophilia a, research		Phase 1Not yet recruiting2025
A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B
2025-521858-42-00 — safety, antibodies, aged, hemophilia a, male		Phase 3Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS